Merck & Co., Inc. (NYSE:MRK) Shares Sold by MainStreet Investment Advisors LLC


Share on StockTwits

MainStreet Investment Advisors LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,033 shares of the company’s stock after selling 6,125 shares during the period. MainStreet Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $5,810,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Catalyst Private Wealth LLC acquired a new stake in Merck & Co., Inc. in the 3rd quarter worth about $25,000. Financial Avengers Inc. acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $28,000. Joseph P. Lucia & Associates LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $29,000. Flagship Private Wealth LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $27,000. Finally, Fiduciary Planning LLC acquired a new stake in Merck & Co., Inc. in the 3rd quarter worth about $32,000. 72.86% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. stock traded down $0.17 during midday trading on Tuesday, hitting $74.76. 328,579 shares of the company were exchanged, compared to its average volume of 10,548,566. The company’s fifty day moving average price is $79.00 and its 200-day moving average price is $80.98. The company has a market cap of $189.15 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. Merck & Co., Inc. has a fifty-two week low of $65.25 and a fifty-two week high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, February 3rd. The company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.06). The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.65 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $1.16 earnings per share. On average, analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 7th. Investors of record on Monday, March 15th will be given a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.48%. The ex-dividend date is Friday, March 12th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.10%.

Several equities analysts have recently weighed in on MRK shares. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, November 10th. Mizuho reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Merck & Co., Inc. in a research note on Sunday, December 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Finally, SVB Leerink lifted their price objective on Merck & Co., Inc. from $100.00 to $103.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $95.36.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products.

Read More: Stop Order

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.